This company listing is no longer active
CTI BioPharma Future Growth
Future criteria checks 5/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for CTI BioPharma.
Key information
60.0%
Earnings growth rate
61.5%
EPS growth rate
| Biotechs earnings growth | 35.1% |
| Revenue growth rate | 34.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 27 Jun 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 309 | 99 | N/A | N/A | 4 |
| 12/31/2024 | 221 | 36 | N/A | N/A | 6 |
| 12/31/2023 | 117 | -39 | N/A | N/A | 4 |
| 3/31/2023 | 76 | -69 | -82 | -82 | N/A |
| 12/31/2022 | 54 | -93 | -81 | -81 | N/A |
| 9/30/2022 | 33 | -112 | -96 | -96 | N/A |
| 6/30/2022 | 15 | -121 | -101 | -101 | N/A |
| 3/31/2022 | 2 | -118 | -98 | -98 | N/A |
| 12/31/2021 | N/A | -98 | -85 | -85 | N/A |
| 9/30/2021 | N/A | -76 | -66 | -66 | N/A |
| 6/30/2021 | N/A | -63 | -57 | -57 | N/A |
| 3/31/2021 | N/A | -58 | -49 | -49 | N/A |
| 12/31/2020 | N/A | -52 | -42 | -42 | N/A |
| 9/30/2020 | N/A | -46 | -43 | -43 | N/A |
| 6/30/2020 | 2 | -44 | -37 | -37 | N/A |
| 3/31/2020 | 3 | -41 | -35 | -35 | N/A |
| 12/31/2019 | 3 | -40 | -28 | -28 | N/A |
| 9/30/2019 | 17 | -31 | -29 | -29 | N/A |
| 6/30/2019 | 16 | -36 | -35 | -35 | N/A |
| 3/31/2019 | 16 | -36 | -41 | -41 | N/A |
| 12/31/2018 | 26 | -29 | -40 | -40 | N/A |
| 9/30/2018 | 13 | -45 | -38 | -38 | N/A |
| 6/30/2018 | 14 | -42 | -46 | -46 | N/A |
| 3/31/2018 | 35 | -29 | -33 | -33 | N/A |
| 12/31/2017 | 25 | -45 | -39 | -39 | N/A |
| 9/30/2017 | 34 | -37 | -43 | -43 | N/A |
| 6/30/2017 | 37 | -54 | -36 | -36 | N/A |
| 3/31/2017 | 22 | -75 | -62 | -62 | N/A |
| 12/31/2016 | 57 | -52 | N/A | -77 | N/A |
| 9/30/2016 | 60 | -74 | N/A | -84 | N/A |
| 6/30/2016 | 56 | -78 | N/A | -95 | N/A |
| 3/31/2016 | 50 | -91 | N/A | -94 | N/A |
| 12/31/2015 | 16 | -123 | N/A | -95 | N/A |
| 9/30/2015 | 23 | -138 | N/A | -69 | N/A |
| 6/30/2015 | 61 | -101 | N/A | -50 | N/A |
| 3/31/2015 | 61 | -96 | N/A | -43 | N/A |
| 12/31/2014 | 60 | -96 | N/A | -40 | N/A |
| 9/30/2014 | 75 | -42 | N/A | -33 | N/A |
| 6/30/2014 | 36 | -69 | N/A | -44 | N/A |
| 3/31/2014 | 35 | -59 | N/A | -41 | N/A |
| 12/31/2013 | 35 | -50 | N/A | -36 | N/A |
| 9/30/2013 | 2 | -79 | N/A | -63 | N/A |
| 6/30/2013 | 1 | -77 | N/A | -60 | N/A |
| 3/31/2013 | 1 | -117 | N/A | -59 | N/A |
| 12/31/2012 | N/A | -115 | N/A | -63 | N/A |
| 9/30/2012 | N/A | -114 | N/A | -51 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CEPS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: CEPS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CEPS is expected to become profitable in the next 3 years.
Revenue vs Market: CEPS's revenue (34% per year) is forecast to grow faster than the German market (3.5% per year).
High Growth Revenue: CEPS's revenue (34% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CEPS's Return on Equity is forecast to be high in 3 years time